← All trials
NCT06824181
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2025
- Primary completion
- May 17, 2027
- Completion date
- May 17, 2027
- First posted
- Feb 13, 2025
- Last posted
- Mar 5, 2025
- Enrollment
- 580
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- SanofiLead sponsor
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- Measles, Mumps and Rubella Vaccine, Live
- rotavirus vaccine, live, oral, pentavalent
- hepatitis a vaccine, inactivated
- live attenuated varicella vaccine
- measles, mumps, and rubella vaccine
- human rotavirus, live attenuated
- 20-valent pneumococcal conjugate vaccine
- Pneumococcal 21-valent conjugate vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.